Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Adds five years of market exclusivity on approval
Subscribe To Our Newsletter & Stay Updated